Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease

We performed a 15-year post-mortem neuropathological follow-up of patients in the first trial of amyloid-β immunotherapy for Alzheimer’s disease. Twenty-two participants of a clinical trial of active amyloid-β(42) immunization (AN1792, Elan Pharmaceuticals) or placebo were studied. Comprehensive pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicoll, James A R, Buckland, George R, Harrison, Charlotte H, Page, Anton, Harris, Scott, Love, Seth, Neal, James W, Holmes, Clive, Boche, Delphine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598630/
https://www.ncbi.nlm.nih.gov/pubmed/31157360
http://dx.doi.org/10.1093/brain/awz142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598630/
https://www.ncbi.nlm.nih.gov/pubmed/31157360
http://dx.doi.org/10.1093/brain/awz142

Ejemplares similares